Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
07:00am, Tuesday, 15'th Dec 2020
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating officer,
- Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins 1 -
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
04:30pm, Tuesday, 10'th Nov 2020
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal a
Esperion: Analysis Of Prospects And Latest Earnings Call
10:35am, Sunday, 08'th Nov 2020
Esperion's approved product bempedoic acid is a non-statin, lipid-lowering drug with proven efficacy. However, high burn rate, poor uptake, and coronavirus have all dampened the prospects of the compa
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05:00pm, Friday, 06'th Nov 2020
ANN ARBOR, Mich., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 4, 2020, the Compensation Committee of Esperion's Board of Directors granted 33,663 restri
Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q3 2020 Results - Earnings Call Transcript
09:58pm, Monday, 02'nd Nov 2020
Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q3 2020 Results - Earnings Call Transcript
Recap: Esperion Therapeutics Q3 Earnings
04:49pm, Monday, 02'nd Nov 2020
Shares of Esperion Therapeutics (NASDAQ:ESPR) fell 2% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 21.83% over the past year to ($3.07), whi
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
04:01pm, Monday, 02'nd Nov 2020
– Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL ® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets –
Esperion to Participate in Three Upcoming Virtual Investor Conferences
08:00am, Tuesday, 27'th Oct 2020
ANN ARBOR, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in three upcoming virtual conferences during the month
Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus
03:10pm, Tuesday, 11'th Aug 2020
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.
Esperion Therapeutics Inc (ESPR) Q2 2020 Earnings Call Transcript
06:30am, Tuesday, 11'th Aug 2020
With me on today's call are Tim Mayleben, President and Chief Executive Officer; Mark Glickman, Chief Commercial Officer; and Rick Bartram, Chief Financial Officer. Actual results could differ materi
Esperion Therapeutics (ESPR) Beats Q2 Earnings Estimates
09:15pm, Monday, 10'th Aug 2020
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 102.82% and -0.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
08:04pm, Monday, 10'th Aug 2020
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million in Cash –– Extraordinary High
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Were Hedge Funds Right About Betting On Esperion Therapeutics (ESPR)?
01:27pm, Friday, 07'th Aug 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market
